Medtronic kicks off Endeavor Resolute studies
This article was originally published in Clinica
Medtronic's next-generation Endeavor Resolute zotarolimus-eluting stent is to enter two new trials. RESOLUTE US will enrol 1,399 patients and use historical data from other Medtronic stent studies as a control. One of the trial's endpoints is the rate of target lesion failure at one year. Data from the trial will be used to seek FDA approval of the stent. RESOLUTE International will enrol up to 2,200 patients to evaluate the device in a "real-world" population. Its primary endpoint is a composite of cardiac death and heart attack rates at one year.